Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India

• Published in: AIDS Research and Treatment Vol. 2012; no. 2012; pp. 1 - 6
• Main Authors: Sinha, Sanjeev, Ahmad, H., Shekhar, R. C., Kumar, N., Dar, L., Samantaray, J. C., Sharma, S. K., Bhargava, A., Pandey, R. M., Mitsuyasu, Ronald T., Fahey, J. L.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 2012; Hindawi Puplishing Corporation; Hindawi Publishing Corporation; Wiley
• ISSN: 2090-1240; 2090-1259
• DOI: 10.1155/2012/905823

Objective. The increased use of antiretroviral therapy (ART) has reduced the morbidity and mortality associated with HIV, adversely leading to the emergence of HIV drug resistance (HIVDR). In this study we aim to evaluate the prevalence of HIVDR mutations in ART-naive HIV-1 infected patients from northern India. Design. Analysis was performed using Viroseq genotyping system based on sequencing of entire protease and two-thirds of the Reverse Transcriptase (RT) region of pol gene. Results. Seventy three chronic HIV-1 infected ART naïve patients eligible for first line ART were enrolled from April 2006 to August 2008. In 68 patients DNA was successfully amplified and sequencing was done. 97% of HIV-1 strains belonged to subtype C, and one each to subtype A1 and subtype B. The overall prevalence of primary DRMs was 2.9% [2/68, 95% confidence interval (CI), 0.3%–10.2%]. One patient had a major RT mutation M184V, known to confer resistance to lamivudine, and another had a major protease inhibitor (PI) mutation D30N that imparts resistance to nelfinavir. Conclusion. Our study shows that primary HIVDR mutations have a prevalence of 2.9% among ART-naive chronic HIV-1 infected individuals.